2. Academic Validation
  3. DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa

DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa

  • Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02122-18. doi: 10.1128/AAC.02122-18.
Manoj Kumar  # 1,  Madhvi Rao  # 2,  Kedar P Purnapatre  # 2,  Tarani Kanta Barman 2,  Vattan Joshi 2,  Amuliya Kashyap 2,  Tridib Chaira 3,  Ramesh B Bambal 3,  Manisha Pandya 2,  Souhaila Al Khodor 4,  Dilip J Upadhyay 2 5,  Nobuhisa Masuda 2
Affiliations

Affiliations

  • 1 Department of Microbiology, Daiichi Sankyo India Pharma Pvt. Ltd., Gurugram, Haryana, India [email protected].
  • 2 Department of Microbiology, Daiichi Sankyo India Pharma Pvt. Ltd., Gurugram, Haryana, India.
  • 3 Department of Pharmacokinetics and Metabolism, Daiichi Sankyo India Pharma Pvt. Ltd., Gurugram, Haryana, India.
  • 4 Department of Immunology, Inflammation and Metabolism, Division of Translational Medicine, SIDRA Medicine, Doha, Qatar.
  • 5 Amity Institute of Virology and Immunology, Amity University, Noida, India.
  • # Contributed equally.
PMID: 30670430 DOI: 10.1128/AAC.02122-18
Abstract

DS86760016 is a new leucyl-tRNA-synthetase inhibitor at the preclinical development stage. DS86760016 showed potent activity against extended-spectrum multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples and in vitro biofilms. In a murine catheter-associated urinary tract Infection model, DS86760016 treatment resulted in significant eradication of P. aeruginosa from the kidney, bladder, and catheter without developing drug resistance. Our data suggest that DS86760016 has the potential to act as a new drug for the treatment of Pseudomonas infections.

Keywords

Gram-negative bacteria; Pseudomonas aeruginosa; UTI; aminoacyl-tRNA synthesis; multidrug resistance.

Figures
Products